Navigation Links
Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
Date:4/18/2008

EATONTOWN, N.J., April 18 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that it has renewed its exclusive tissue recovery agreement with The Euro Atlantic Transplant Alliance ("EATA"), a Bulgarian public non-profit foundation. The agreement, which was effective April 1, 2008, is for an initial term of seven years and automatically renews for successive four year terms unless a written notice of intent to terminate is provided by either party at least twelve months prior to the end of the initial, or any renewal term. This new agreement replaces a previous agreement that was due to expire in early 2009.

Sam Owusu-Akyaw, President and Chief Executive Officer of Osteotech, stated, "We are very pleased to renew our relationship with the Republic of Bulgaria and the EATA. Through the tissue recovery efforts of both organizations over the past five years, Osteotech has been able to use its processing and product technologies to bring safe and clinically effective OsteoBiologic products to the European market for use by surgeons to alleviate pain, promote biologic healing and restore function."

Dr. Roman A. Hitchev, President and Chief Medical Officer of TB Osteocentre Bulgaria EAD, an indirect wholly-owned subsidiary of Osteotech, commented, "We have had an excellent working relationship with the EATA over the last five years and together have established a successful tissue recovery system in the Republic of Bulgaria. We look forward to continuing our outstanding relationship with the EATA and, working with the EATA, to successfully integrate the Bulgarian tissue recovery and transplantation system into the tissue exchange
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Osteotech Announces First Quarter Earnings Release and Conference Call Schedule
2. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
3. Osteotech to Present at the Sidoti Conference in New York
4. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
5. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
6. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
7. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
8. Osteotech to Present at Sidoti Conference in San Francisco
9. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
10. Biomaxx Systems Inc. Renews Membership With Bioenergy Australia
11. Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
(Date:7/24/2014)... -- Neogen Corporation (Nasdaq: NEOG ) advised market ... from new rodenticide research are premature. In its regular ... 22, 2014, Neogen,s CEO commented about several new developments ... "It was my intent Tuesday at our conference call ... type of rodenticide, but certainly not to give any ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... CV Therapeutics, Inc. (Nasdaq: CVTX ) today ... and rejected the previously announced unsolicited proposal from Astellas ... of $16.00 per share. After careful consideration of ... the CV Therapeutics board concluded that the Astellas proposal ...
... February 20 Nyenrode Business,Universiteit has awarded a ... the field of microeconomics, competitive strategy and cluster,theory. ... of the modern,field of strategy and the world,s ... and competitive strategy. Professor Porter will receive,the Honorary ...
... Guidance of $0.90 to $1.10 for 2009 and $1.50 to $1.70 ... ) today announced its financial results for the three and twelve ... of $0.90 to $1.10 for 2009 and $1.50 to $1.70 for ... Adjusted diluted EPS of $0.26 ...
Cached Biology Technology:CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 2CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 3CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 4Nyenrode Honorary Doctorate for Professor Michael E. Porter 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 3Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 4Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 5Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 6Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 7Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 8Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 9Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 10Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 11Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 12Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 13Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 14Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 15Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 16Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 17
(Date:7/24/2014)... Parts of the primordial soup in which life arose have ... the University of East Anglia. , Research published today in ... in plants, yeast and very likely also in animals still ... origin of life some four billion years ago. , ... pond or ocean as a result of the combination of ...
(Date:7/24/2014)... Africa in mid-July 2014, as the annual fire season ... areas of increased temperatures, are heavily sprinkled across the ... Congo (northeast), and Zambia (southeast). Thick gray smoke rises ... especially in the Democratic Republic of the Congo, strong ... fire season is an annual event in this region, ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... group of European experts on biodiversity will gather from the ... to further improve the transfer of biodiversity knowledge from the ... will take part in a project funded by the European ... by researchers and practitioners to help all actors in the ...
... in milk powder and in meat-based baby food, residues ... the University of Almera (Spain) have developed a system ... such as tilmicosine, or antiparasitic drugs, such as levamisole, ... but they can remain later in food. Scientists from ...
... genetic testing that can indicate their range of risk ... appreciably drive up or diminish test recipients, demand for ... performed by researchers at the National Institutes of Health ... the May 17, 2012 early online issue of ...
Cached Biology News:A network of knowledge on biodiversity and ecosystem services in Europe 2A new method detects traces of veterinary drugs in baby food 2NIH-led study finds genetic test results do not trigger increased use of health services 2NIH-led study finds genetic test results do not trigger increased use of health services 3NIH-led study finds genetic test results do not trigger increased use of health services 4
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
Mouse Limitin MAb (Clone 183727)...
Biology Products: